Immediate revascularization of nonculprit lesions in patients with STEMI was not superior compared with deferred percutaneous coronary intervention of nonculprit lesions out to 3 years, researchers reported.
Risks for all-cause death, recurrent MI and heart failure hospitalization were all similar between an instantaneous wave-free ratio-guided immediate PCI strategy of nonculprit lesions compared with MRI-guided deferred PCI, according to the study.
The results of the international, investigator-initiated, open-label, randomized controlled iMODERN trial were published in The New England

Women have a longer life expectancy than men, but those born since the 1930s have worse cancer mortality due to female reproductive tumors.
An analysis of low-mortality countries showed women survive 4 to 8 years longer than men in these areas, but the gap would widen further if not for breast and gynecologic cancers, including 0.7 years in the U.S.
“We estimate that one half to a full year could be achieved of extra survival for females across those countries if the excess female reproductive cancer mortality disappeared,” Vladimir Canudas-Romo, PhD, professor in the school of demography at

Women with hypothyroidism receiving levothyroxine treatment have similar cardiovascular disease risk as those without thyroid disease, according to data published in Thyroid.
In an analysis of 2,647 women who participated in the Study of Women’s Health Across the Nation (SWAN), a similar percentage of women with hypothyroidism treated with levothyroxine had a CV event occur as women without thyroid disease. Matthew Ettleson, MD, assistant professor of medicine at University of Chicago, said the findings should be “reassuring” for health care professionals prescribing levothyroxine therapy for

Chronic wounds are an immense burden for patients. If left untreated, chronic wounds can be life-threatening, making effective diagnosis and treatment vital for wound care.
In this Beneath the Surface video interview, Joel M. Gelfand, MD, MSCE, FAAD, the James J. Leyden Professor of Clinical Investigation and professor of dermatology and epidemiology at University of Pennsylvania’s Perelman School of Medicine and Healio Dermatology’s Chief Medical Editor, spoke with Robert S. Kirsner, MD, PhD, chairman and professor at the department of dermatology and cutaneous surgery at University of Miami

A once-weekly amylin analog conferred up to 10.7% weight loss at 42 weeks among adults with overweight or obesity and featured a safety profile similar to placebo, according to topline results from the ZUPREME-1 trial.
Petrelintide (Roche) is a once-weekly injectable medication currently under development for the treatment of obesity. In a phase 2 trial, 493 adults with obesity or overweight plus weight-related comorbidities were randomly assigned to one of five treatment arms receiving once-weekly petrelintide or placebo for 42 weeks (mean age, 48 years; 53% women). The primary outcome was

We often think of AI as something on the horizon, something our organization will eventually adopt and integrate into our clinical and administrative workflows.
We hear about its potential at conferences, in vendor presentations and in articles predicting how it will reshape medicine in the years ahead.
However, AI raises an immediate question worth asking: What if AI is already being used inside your practice, and you simply have not recognized or acknowledged it yet?
A physician pastes a patient portal message into an AI tool to help draft a reply. A staff member uploads a spreadsheet with

Individuals with chronic back pain reported significantly higher levels of auditory sensitivity compared with pain-free controls, but therapy may mitigate this sensitivity, according to findings published in Annals of Neurology.
“There is a growing recognition that chronic pain is often driven by brain sensitization, or sensory amplification, but it is not clear how wide this sensitization/amplification extends, across sensory modalities,” Yoni K. Ashar, PhD, assistant professor in the division of internal medicine at the University of Colorado Anschutz Medical Campus, told Healio.
“We

PHILADELPHIA — After 12 months of treatment, more 4- to 7-year-olds with peanut allergy using the Viaskin Peanut patch vs. placebo were deemed treatment responders, according to data presented here.
Additionally, more than 80% of Viaskin Peanut patch (VP250; DBV Technologies) users had an eliciting dose increase of at least two doses or one dose at month 12, according to the presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
“You want things that are practical and easy to use for patients and safe and effective as well, and I think this product meets these

Historic redlining, a U.S. policy outlawed nearly 6 decades ago for segregating neighborhoods based on their racial makeup, still negatively impacts survival from breast cancer, according to results of a population-based cohort study.
Findings showed women who lived in redlined neighborhoods had significantly worse 5-year survival than those who resided in A-graded neighborhoods. Overall survival disparities were greatest from 1995 to 1999, narrowed in subsequent years and widened again from 2015 to 2019.
“It is disappointing,” Sarah M. Lima, PhD, MPH, postdoctoral fellow in cancer prevention

In this video, Maria Caterina Rotiroti, PhD, discusses the challenge of treating antigen-low disease with chimeric antigen receptor T-cell therapy, as well as a possible solution that could “boost” performance.
The findings were presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.
“Relapse with antigen-low [disease] has emerged in the clinic after CAR T-cell therapy,” Rotiroti, a postdoctoral fellow at Dana-Farber Cancer Institute, told Healio. “In our lab, we decided to address this challenge by engineering the